First in class study of an investigational ACTH receptor antagonist aims to address significant unmet need in children and adolescents…
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia and…
Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PT…
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued…
January 04, 2026 16:00 ET | Source: Crinetics Pharmaceuticals, Inc. SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals,…
The secondary analysis of the PACE trial highlights the value of counting Circulating Tumor Cells (CTCs) in the blood to…
SAN DIEGO, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company advancing small-molecule inhibition of…
December 17, 2025 20:48 ET | Source: InnoCare Pharma BEIJING, Dec. 17, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969;…
BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the…
December 10, 2025 04:00 ET | Source: Igyxos TOURS, France, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Igyxos Biotherapeutics, a biotechnology…